Please Note:
This profile was automatically generated using 17 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 17 references found on the Internet. This information has not been verified. Learn more...
View all 17 references Web References
-
1. pharma.dow.com
pharma.dow.com/pharma/sm_molec - [Cached]Published on: 10/3/2006 Last Visited: 5/11/2008
"Asymmetric chemocatalysis technologies have come of age for the cost-effective manufacture of APIs and intermediates; Dowpharma is at the stage, with the portfolio of drugs that we support, where we needed to further expand our commercial catalyst supply base," says Dr . Mark Cassidy, business director, Small Molecules, Dowpharma.
"We currently supply a number of commercial and late-phase clinical drugs, and over 10 of our catalytic systems have been operated at commercial scale, including the rhodium DuPhosÔ catalysts for asymmetric hydrogenation," says Cassidy."Having a demonstrated and commercially proven capability is important; our customers already face enough uncertainties in developing their drugs without compounding risk with commercially unproven or non-scaleable technology."
"Developing the right technology is only part of it," adds Cassidy. -
2. Dow and Avidex Agree to Develop Biotargeted Radiopharmaceuticals based on mTCR Technology
www.pharma.dow.com/pharma/chel - [Cached]Published on: 9/2/2003 Last Visited: 12/16/2006
"We are excited about using Dow's capabilities in chelation, conjugation, process and radiochemistry to enable Avidex to develop novel radiopharmaceuticals," said Dow's Mark Cassidy, PhD, Director, Pharmaceutical Technologies. -
3. pharma.dow.com
pharma.dow.com/pharma/sm_molec - [Cached]Published on: 6/13/2006 Last Visited: 5/11/2008
"We are delighted to be entering into this collaboration with Aquapharm," said Dr. Mark Cassidy, Director, Small Molecules for Dowpharma."Dowpharma contract manufacturing services has a more than 15 year track record of successfully using biocatalysis for the preparation of small molecule intermediates for the pharmaceutical industry".Dowpharma has experience in applying lipases, esterases, acylases, nitrilases, amidases and alcohol dehydogenases, Cassidy noted."We are committed to extending our biocatalysis capabilities by discovering new enzymes.Access to the marine micro-organisms from Aquapharm will increase the diversity of our existing collection of wild type organisms, allowing us to discover and commercially develop differentiated solutions for the preparation of our customers' targets," added Cassidy.
